nach oben

Drugs & Aging

Erschienen in:

01.12.2001 | Therapy In Practice

Strategies for Management of Prostate Cancer-Related Bone Pain

verfasst von: Rob C. M. Pelger, Vidija Soerdjbalie-Maikoe, Neveen A. T. Hamdy

Erschienen in: Drugs & Aging | Ausgabe 12/2001

Einloggen, um Zugang zu erhalten

Abstract

Prostate cancer is one of the most common malignancies and a leading cause of cancer-related death in men worldwide. In the majority of cases, prostate cancer metastasises to the skeleton, in which case cancer-related bone pain becomes a major cause of morbidity. Androgen ablation is the treatment of choice for securing regression of skeletal metastases in the majority of cases. Intermittent androgen ablation is an attractive alternative, aimed at minimising adverse effects of hormone deprivation but also potentially delaying hormone-refractoriness. The development of hormone-refractoriness is heralded by a significant increase in morbidity largely because of escalating bone pain caused by the progression of the metastatic process. Skilful use of analgesics is initially successful but eventually fails to control symptoms. Localised metastases are best treated with local radiotherapy that is rapidly effective. Over the last few years, it has become clear that therapeutic modalities using bone-seeking radionuclides or bisphosphonates have been effective in the palliation of prostate cancer-related bone pain, although not affecting survival. The main limiting factor with the use of radionuclides is bone marrow suppression, also a feature of the very late stages of prostate cancer. Bisphosphonates do not carry this disadvantage. Results of large double-blind, placebo-controlled studies should be awaited, however, before advocating the widespread use of these agents in the management of patients with prostate cancer and skeletal metastases.

Parker SL, Tong T, Bolden S, et al. Cancer statistics 1996. CA Cancer J Clin 1996; 46: 5–27PubMedCrossRef

Dale A. Office of population censuses and survey. Cancer statistics, England and Wales. London: HMSO Series MBI, 1996

Post PN, Straatman H, Kiemeney LA, et al. Increased risk of fatal prostate cancer may explain the rise of mortality in the Netherlands. Int J Epidemiol 1999; 28: 403–8PubMedCrossRef

Visser O, Coebergh JW, Schouten LJ, et al, editors. Incidence of cancer in the Netherlands 1997. Utrecht: Association of Comprehensive Cancer Centres, 2001

Jacobs SC. Spread of prostatic cancer to bone. Urology 1983; 21: 337–44PubMedCrossRef

Franks LM. The spread of prostatic carcinoma. J Pathol Bacte-riol 1956; 72: 603–11CrossRef

Abrams HL. Skeletal metastases in carcinoma. Radiology 1950; 55: 534–8PubMed

Turner JW, Jaffe HL. Metastatic neoplasms. A clinical and roentgenological study of involvement of skeleton and lungs. Am J Roentgenol 1940; 43: 479

Elkin M, Mueller HP. Metastases from cancer of the prostate. Cancer 1954; 7: 1246–8PubMedCrossRef

10.

Orr FW, Lee J, Duivenvoorden WCM, et al. Pathophysiologic interactions in skeletal metastasis. Cancer 2000; 88: 2912–8PubMedCrossRef

11.

Pantel K, Cote RJ, Fodstad O. Detection and clinical importance of micrometastasic disease. J Natl Cancer Inst 1999; 91: 1113–24PubMedCrossRef

12.

Carter RL. Patterns and mechanisms of bone metastases. J R Soc Med 1985; 78 Suppl. 9: 2–6PubMed

13.

Stoll BA. Natural history, prognosis and staging of bone metastases. In: Stoll BA, Parbhoo S, editors. Bone metastases: monitoring and treatment. New York: Raven, 1983: 1–20

14.

Guise T, Mundy G. Cancer and bone. Endocr Rev 1998; 19: 18–54PubMedCrossRef

15.

Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol 1991; 9(3): 509–24PubMed

16.

Galasko CSB. Mechanisms of lytic and blastic metastatic disease of bone. Clin Orthop 1982; 169: 20–7PubMed

17.

Paterson AHG. Bone metastases in breast cancer, prostate cancer and myeloma. Bone 1987; 8 Suppl. 1: 17–22

18.

Mundy GR. Bone resorption and turnover in health and disease. Bone 1987; 8 Suppl. 1: 9–16

19.

Batson OV. The function of the vertebral veins and their role in the spread of metastases. Ann Surg 1940; 112: 138–49PubMedCrossRef

20.

Manishen JW, Sivananthan K, Orr FW. Resorbing bone stimulates tumor cell growth. Am J Pathol 1986; 123: 39–45PubMed

21.

Hauschka PV, Mavrakos AE, Iafrati MD, et al. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin sepharose. J Biol Chem 1986; 261: 12665–74PubMed

22.

Pfeilschifter J, Mundy GR. Modulation of type β transforming growth factor activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci U S A 1987; 84: 2024–8PubMedCrossRef

23.

Powell GJ, Southby J, Danks JA, et al. Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res 1991; 51: 3059–61PubMed

24.

Vargas SJ, Gillespie MT, Powell GJ, et al. Localization of parathyroid hormone-related protein mRNA expression and metastatic lesions by in situ hybridization. J Bone Miner Res 1992; 7: 971–80PubMedCrossRef

25.

Bouizar Z, Spyratos F, Deytieux S, et al. Polymerase chain reaction analysis of parathyroid hormone-related protein gene expression in breast cancer patients and occurrence of bone metastases. Cancer Res 1993; 53: 5076–8PubMed

26.

Asadi F, Farraj M, Sharifi R, et al. Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia. Hum Pathol 1996; 27: 1319–23PubMedCrossRef

27.

Rabanni SA, Gladu J, Harakidas P, et al. Overproduction of parathyroid hormone-related peptide results in increased osteolytic skeletal metastases by prostate cancer cells in vivo. Int J Cancer 1999; 18: 257–64

28.

Burton DW, Tu S, Smith KC, et al. PTHrP processed peptides regulate prostate cell growth. Bone 1998; 23: 1423

29.

Mundy GR. Mechanisms of bone metastases. Cancer 1997; 80: 1546–56PubMedCrossRef

30.

Ikeda I, Miura T, Kondo I. Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer. Br J Urol 1996; 77: 102–6PubMedCrossRef

31.

Goltzman D. Mechanisms of the development of osteoblastic metastases. Cancer 1997; 80 Suppl. 8: 1546–56

32.

Deftos LJ. Granin-A, parathyroid hormone related protein, and calcitonin gene products in neuroendocrine prostate cancer. Prostate 1998; 8: 23–31PubMedCrossRef

33.

Urwin G, Percival R, Harris S, et al. Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol 1985; 57: 721–3PubMedCrossRef

34.

Charhon S, Chapuy MC, Delvin EE, et al. Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma with special reference to osteomalacia. Cancer 1983; 51: 918–24PubMedCrossRef

35.

Percival RC, Urwin GH, Harris S, et al. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol 1978; 13: 41–9

36.

Goltzman D. Mechanisms of development of osteoblastic metatstases. Cancer 1997; 80 Suppl. 8: 1581S–7SCrossRef

37.

Clarke NW, McClure J, George NJR. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol 1991;68:74–80PubMedCrossRef

38.

Taube T, Kylmälä T, Lamberg-Allardt C, et al. The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report on double blind randomized placebo-controlled study. Eur J Cancer 1994; 30: 751–8CrossRef

39.

Thomas RJ, Guise TA, Yin JJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999; 140: 4451–8PubMedCrossRef

40.

Berretoni BA, Carter JR. Mechanisms of Cancer Metastasis to Bone. J Bone and Joint Surg 1986; 68A: 308–12

41.

Willems A. Secondary tumours of bones. In: The spread of tumours in the human body. 3rd ed. London: Butterworth, 1973: 229–250

42.

Lote K, Walloe A, Bjersand A. Bone metastases. Prognosis, diagnosis and treatment. Acta Radiol Oncol 1986; 25: 227–32PubMedCrossRef

43.

Mauch PM, Drew MA. Treatment of metastatic cancer to bone. In: De Vita Jr VT, Helleman S, Rosenberg SA, et al. Cancer, principles & practice of oncology. Philadelphia (PA): Lippincott, 1985: 2132–2141

44.

Malawer MM, Delaney TF. Treatment of metastatic cancer to bone. In: De Vita Jr VT, Hellman S, Rosenberg SA, et al. Cancer, principles & practice of oncology. Philadelphia (PA): Lippincott, 1985: 2298–2317

45.

Miller F, Whitehill R. Carcinoma of the breast metastatic to the skeleton. Clin Orthop 1984; 184: 121–7PubMed

46.

Bhalla SK. Metastatic disease of the spine. Clin Orthop 1970; 73: 52–60PubMed

47.

Drew M, Dickson RB. Osseous complications of malignancy. In: Lokich JJ, editor. Clinical cancer medicine: treatment tactics. Boston: GK Hall, 1980: 97

48.

Enneking WF. Metastatic carcinoma. Musculoskeletal tumor surgery. Vol. 2. New York: Churchill Livingstone, 1983: 1541

49.

Chisholm GD, Rana A, Howard GCW. Management options for painful carcinoma of the prostate. Sem Oncol 1993; 20 (3 Suppl. 2): 34–7

50.

Tofe AJ, Francis MD, Harvey WJ. Correlations of neoplasms with incidence and localization of bone metastases: an analysis of 1,355 diphosphonate bone scans. J Nucl Med 1975; 16: 986–9PubMed

51.

Rubens RD. The nature of metastatic bone disease. In: Rubens Rd, Fogelman I, editors. Bone metastases: diagnosis and treatment. London: Springer-Verlag, 1991: 1–10

52.

Klotz L. Hormone Therapy for patients with prostate carcinoma. Cancer 2000; 88 Suppl. 12: 3009–14PubMedCrossRef

53.

Huggins C, Hodges CV. Studies on prostate cancer: the effect of estrogens and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–7

54.

Schroder FH. Endocrine treatment of prostrate cancer. In: Walsh PC, Retik AB, Vaughan ED, et al., editors. Campbell Urology. Vol. 3. Philadelphia: WB Saunders Company, 1998: 2627–44

55.

Daniell HW. Osteoporosis after orchidectomy for prostate cancer. J Urol 1997; 157: 439–44PubMedCrossRef

56.

Fossa SD, Dearnaley DP, Law M. Prognostic factors in hormone-resistant progressing cancer of the prostate. Ann Oncol 1992; 3: 361–6PubMed

57.

Goldenberg SL, Bruchovsky N, Gleave ME, et al. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 1995; 45: 839–45PubMedCrossRef

58.

John A, Campa L, Payne R. The management of intractable bone pain: a clinicians perspective. Semin Nucl Med 1992; 22: 3–10

59.

Inturrisi C. Management of cancer pain. Cancer 1989; 63: 2308–20PubMedCrossRef

60.

Benson Jr RC, Hasa SM, Jones AG, et al. External beam radiotherapy for palliation of pain for metastatic carcinoma of the prostate. J Urol 1982; 127: 69–71PubMed

61.

Kynaston HG, Keen CW, Matthews PN. Radiotherapy for palliation of locally advanced prostatic cancer. Br J Urol 1990; 66: 515–7PubMedCrossRef

62.

Winston MA. Radioisotope therapy in bone and joint disease. Semin Nucl Med 1979; 2: 114–9

63.

Hamdy NAT, Papapoulos SE. The palliative management of skeletal metastases in prostate cancer: use of bone-seeking radionuclides and bisphosphonates. Semin Nucl Med 2001; 31: 62–8PubMedCrossRef

64.

Pauwels EWJ, Stokkel MPM. Radiopharmaceuticals for bone lesions. Imaging and therapy in clinical practise. Q J Nucl Med 2001:45; 18–26PubMed

65.

Serafini AN. Therapy of metastatic bone pain. J Nucl Med 2001:42; 895–906PubMed

66.

Pecher C. Biological investigations with radioactive calcium and strontium: preliminary report on the use of radioactive strontium in the treatment of metastatic bone cancer. Los Angeles (CA). University of California Publications in Pharmacology 1942; 2: 117–49

67.

Lawrence JH, Wasserman Jr LR. Multiple myeloma: a study of 24 patients treated with radioactive isotopes (32P and 89Sr). Ann Intern Med 1950; 33: 41–55PubMed

68.

Robinson RG, Blake GM, Preston DF, et al. 89Strontium treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics 1989; 9: 271–81PubMed

69.

Blake GM, Zivanovic MA, McEwan AJ, et al. Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 1986; 12: 447–54PubMed

70.

Robinson RG, Spicer JA, Preston DF, et al. Treatment of metastatic bone pain with 89strontium. Nucl Med Biol 1987; 14: 219–22

71.

Silberstein EB, Williams C. Strontium-89 therapy for the pain of osseous metastases. J Nucl Med 1985; 26: 345–8PubMed

72.

Reddy EK, Robinson RG, Mansfield CM. Strontium-89 for palliation of bone metastases. J Natl Med Assoc 1986; 78: 27–32PubMed

73.

Kloiber R, Molnar CP, Barnes M. Sr-89 therapy for metastatic bone disease: scintigraphic and radiographic follow up. Radiology 1987; 163:719–23PubMed

74.

Tennvall J, Darte L, Lundgren R, et al. Palliation of multiple bone metastases from prostatic carcinoma with strontium-89. Acta Oncol 1988; 27:365–9PubMedCrossRef

75.

Buchali K, Correns HJ, Schuerer M, et al. Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. Eur J Nucl Med 1988; 14: 349–51PubMedCrossRef

76.

McEwan AJB, Porter AT, Venner PM, et al. An evaluation of the safety and efficacy of treatment with Strontium-89 in patients who have previously received wide field radiotherapy. Antibody, Immunoconjug Radiopharm 1990; 3: 91–8

77.

Laing AH, Ackery DM, Bayly RJ, et al. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol 1991; 64: 816–22PubMedCrossRef

78.

Fossa SD, Paus E, Lochoff M, et al. 89Strontium in bone metastases from hormone resistant prostate cancer: Palliation effect and biochemical changes. Br J Cancer 1992; 66: 177–80PubMedCrossRef

79.

Dearnaly DP, Bayly RJ, A’Hern RP, et al. Palliation of bone metastases in prostate cancer. Hemibody irradiation or Strontium-89? Clin Oncol 1992; 4: 101–7CrossRef

80.

Mertens WC, Porter AT, Reid RH, et al. Strontium-89 and low-infusion cisplatin for patients with hormone-refractory prostate carcinoma metastatic to bone: a preliminary report. J Nucl Med 1992; 33: 1437–43PubMed

81.

Kovner F, Ron IG, Levita M, et al. Strontium-89 therapy in a patient with carcinoma of unknown origin and incurable pain from bone metastases. J Pain Symptom Manage 1993; 8: 47–51PubMedCrossRef

82.

Hansen DV, Holmes ER, Catton G, et al. Strontium-89 therapy for painful osseous metastatic prostate and breast cancer. Am Fam Physician 1993; 47: 1795–800PubMed

83.

Guerrieri P, Modoni S, Parisi S, et al. Bone formation markers and pain palliation in bone metastases treated with Strontium-89. Am J Clin Oncol 1994; 17: 77–9PubMedCrossRef

84.

Robinson RG, Preston DF, Schiefelbein M, et al. Strontium-89 therapy for the palliation of pain due to osseous metastases. JAMA 1995; 274: 420–4PubMedCrossRef

85.

Quilty PM, Kirk D, Boiger JJ, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994; 31: 33–40PubMedCrossRef

86.

Berna L, Carrio I, Alonso C, et al. Bone pain palliation with strontium-89 in breast cancer patients with bone metastases and refractory bone pain. Eur J Nucl Med 1995; 22: 1101–4PubMedCrossRef

87.

Sciuto R, Maini CL, Tofani A, et al. Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89. Nucl Med Commun 1996; 17: 799–804PubMedCrossRef

88.

Patel BR, Flowers WM. Systemic radionuclide therapy with strontium-89 in skeletal metastases in prostate and breast cancer. South Med J 1997; 90: 506–8PubMedCrossRef

89.

Pons F, Herranz R, Garcia A, et al. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer. Eur J Nucl Med 1997; 24: 1210–4PubMedCrossRef

90.

Baziotis N, Yakoumakis E, Zissimopoulos A, et al. Strontium-89 chloride in the treatment of bone metastases in breast cancer. Oncology 1998; 55: 377–81PubMedCrossRef

91.

Kasalick J, Krajská V. The effect of repeated strontium-89 chloride therapy on bone palliation in patients with skeletal cancer metastases. Eur J Nucl Med 1998; 25: 1362–7CrossRef

92.

Jager PL, Mensink HJ, Van den Bergh AC, et al. A Strontium-89 injection: simple treatment of painful bone metastases in patients with prostate cancer unresponsive to hormonal treatment. Ned Tijdschr Geneeskd 1999; 143: 969–73PubMed

93.

Nair N. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases. J Nucl Med 1999; 40: 256–61PubMed

94.

McEwan AJB. Unsealed source therapy of painful bone metastases: an update. Sem Nucl Med 1997; 27: 165–82CrossRef

95.

Turner JH, Martindale AA, Sorby P, et al. Samarium-153-EDTMP therapy of disseminated skeletal metastases. Eur J Nucl Med 1989; 15:784–95PubMedCrossRef

96.

Farhangi M, Holmes RA, Volkert RA, et al. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med 1992; 33: 1451–8

97.

Ahonen A, Joensuu H, Hiltunen J, et al. Samarium-153-EDTMP in bone metastases. J Nucl Biol Med 1994; 38: 123–7PubMed

98.

Resche I, Chantal JF, Pecking A, et al. A dose-controlled study Sm-153-EDTMP in the treatment of patients with painful bone metastases. Eur J Cancer 1997; 33: 1583–91PubMedCrossRef

99.

Sartor O, Quick R, Reid R, et al. A double-blinded placebo controlled study of Sm-153-EDTMP for the palliation of bone pain in patients with hormone refractory prostate carcinoma. J Urol 1997; 157: 321

100.

Serafini AN, Houston SJ, Resche I, et al. Palliation of bone pain associated with metastatic bone cancer using Samarium-153 Lexidronam: a double-blind placebo controlled clinical trial. J Clin Oncol 1998; 16: 1574–81PubMed

101.

Tian JH, Zhang JM, Hou QT, et al. Multicenter trial on the efficacy and toxicity of single dose samarium-153 ethylenediamine methylene phosphonate as a palliative treatment for painful skeletal metatstases in China. Eur J Nucl Med 1999; 26: 2–7PubMedCrossRef

102.

Olea E, Riccabona G, Tian J, et al. Efficacy and toxicity of 153Sm EDTMPin the palliative treatment of painful skeletal metastases: results of an IAEA international multicenter study. J Nucl Med 2000; 41: 146

103.

Cameron PJ, Klemp PF, Martindale AA, et al. Prospective 153Sm-EDTMP therapy dosimetry by whole-body scintigraphy. Nucl Med Commun 1999; 20: 609–15PubMedCrossRef

104.

Bushneil D, Quick D, Reid D. Multiple administration of sm-153-lexidronam in the treatment of painful bone metastases. J Nucl Med 1998; 39: Al 13

105.

Bushneil DL, Menda Y. Retreatment of patients with metastatic bone disease with multiple doses of samarium. Case Stud Oncol 1999; 1: 1–8

106.

Goeckeler WF, Edwards B, Volkert WA, et al. Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. J Nucl Med 1987; 28: 495–504PubMed

107.

de Klerk JM, van Dijk A, van het Schip AD, et al. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. J Nucl Med 1992; 33: 646–51PubMed

108.

Atkins HL, Mausner LF, Srivastava SC, et al. Biodistribution of Sn-117m(4+)DTPA for palliative therapy of painful osseous metastases. Radiology 1993; 186: 279–83PubMed

109.

Tu SM, Delpassand ES, Jones D, et al. Strontium-89 combined with doxorubicin in the treatment of patients with androgenindependent prostate cancer. Urol Oncol 1996; 2: 191–7PubMedCrossRef

110.

Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001: 357; 336–341PubMedCrossRef

111.

Menschutkin N. Ueber die Einwirkung des Chloracetyls auf phosphorige Sáure. Ann Chem Pharm 1865; 133: 317–20CrossRef

112.

Fleisch H, Biaz S. Isolation from urine of pyrophosphate, a calcification inhibitor. Am J Physiol 1962; 203: 671–5PubMed

113.

Fleisch H, Russell RGG, Bisaz S, et al. The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution of calcium phosphate in vitro and in vivo. Calcif Tissue Res 1968; Suppl. 10: 10A

114.

Bisaz S, Jung A, Fleisch H. Uptake by bone of pyrophosphate, diphosphonates and their technetium derivatives. Clin Sci Mol Med 1978; 54: 265–8PubMed

115.

Reitsma PH, Bijvoet OLM, Verlinden-Ooms H, et al. Kinetic Studies of bone and mineral metabolism during treatment with (3-amino-l-hydroxypropylidene 0-1, 1-bisphosphonate (APD) in rats. Calcif Tissue Int 1980; 32: 145–57PubMedCrossRef

116.

Sietsema WK, Ebetino FH, Salvagno AM, et al. An tires orptive dose-relationships across three generations of bisphosphonates. Drugs Exp Clin Res 1989; 9: 389–96

117.

Boonekamp PM, Lowik CWGM, van der Wee-Pals LJA, et al. Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino-group. Bone Miner 1987; 2: 29–42PubMed

118.

Schenk A, Eggli P, Fleisch H, et al. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 1986; 38: 342–9PubMedCrossRef

119.

Fleisch H, Russell RGG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone-resorption in tissue culture and in vivo. Science 1969; 165: 1262–4PubMedCrossRef

120.

Fleish H. Bisphosphonates in bone disease. London: Academic Press, 2000

121.

Frith JC, Monkkonen J, Blackburn GM, et al. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5’-β, y-dichloromethylene triphosphate, by mammalian cells in vitro. J Bone Miner Res 1996; 12: 1358–67CrossRef

122.

Russell RGG, Rogers MJ, Frith JC, et al. The pharmacology of bisphosphonates and new insights into their mechanism of action. J Bone Miner Res 1999; 14 Suppl. 2: 56–65

123.

Rogers MJ, Frith JC, Luckman SP, et al. Molecular mechanism of action of bisphosphonates. Bone 1999; 24: 73S–9SPubMedCrossRef

124.

Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of gtp-binding proteins including ras. J Bone Miner Res 1998; 13: 581–9PubMedCrossRef

125.

Van Beek E, Löwik C, van der Pluijm G, et al. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone expiants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 1999; 14: 722–9CrossRef

126.

Fisher JE, Rogers MJ, Halasy JM, et al. Mechanism of action of alendronate: geranylgeraniol, an intermediate of the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activity in vitro. Proc Natl Acad Sci USA 1999; 96: 133–8PubMedCrossRef

127.

Van Beek E, Pieterman E, Cohen L, et al. Nitrogen-containing bisphosphonates inhibit isopentyl pyrophosphate isomerase/farnesyl pyrophosphate synthetase activity with relative potencies corresponding to their an tires orptive potencies in vitro and in vivo. Biochem Biophys Res Commun 1999; 255:491–4PubMedCrossRef

128.

Reitsma PH, Teitelbaum SL, Bijvoet OLM, et al. Differential action of the bisphosphonates (3 amino-1-hydroxypropy lidene)-1,1-bisphosphonate (APD) and disodium dichloromethyl-idene bisphosphonate (C12MDP) on rat macrophage-mediated bone resorption in vitro. J Clin Invest 1982; 70: 927–33PubMedCrossRef

129.

Schipman CM, Croucher PI, Russell RGR, et al. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998; 58: 5294–7

130.

Aparicio A, Gardner A, Tu Y, et al. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998; 12: 220–9PubMedCrossRef

131.

Busch M, Rave-Fränk M, Hille A, et al. Influence of clodronate on breast cancer cells in vitro. Eur J Med Res 1998; 3: 427–31PubMed

132.

Fromigue D, Siwek B, Body JJ. Bisphosphonates inhibit breast cancer cell proliferation [abstract]. Calcif Tissue Int 1999; 64 Suppl. 1: P–261

133.

Van der Pluijm G, Vloedgraven H, van Beek E, et al. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996; 98: 698–705PubMedCrossRef

134.

Boissier S, Magnetto S, Frappart L, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to un-mineralized and mineralized bone extracellular matrices. Cancer Res 1997; 57: 3890–4PubMed

135.

Maeda H, Koizumi M, Yoshimura K, et al. Correlation between bone metabolic markers and bone scan in prostatic cancer. J Urol 1997; 157:539–43PubMedCrossRef

136.

Kylmälä T, Tammela T, Risteli L, et al. Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. Eur J Cancer 1993; 29A: 821–5PubMedCrossRef

137.

Pelger RCM, Hamdy NAT, Zwinderman AH, et al. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone 1998; 22: 403–8PubMedCrossRef

138.

Vinholes JJF, Purohit OP, Abbey ME, et al. Relationships between biochemical and symptomatic response in a double-blind randomised trial of Pamidronate for metastatic bone disease. Ann Oncol 1997; 8: 1243–50PubMedCrossRef

139.

Adami S.Bisphosphonates in prostate carcinoma. Cancer 1997; 80: 1674–9

140.

Papapoulos SE, Hamdy NAT, van der Pluijm G. Bisphosphonates in the management of prostate carcinoma metastatic to the skeleton. Cancer 2000; 88: 3047–53PubMedCrossRef

141.

Smith JA. Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double blind, placebo controlled study. J Urol 1989; 141:85–7PubMed

142.

Carey P, Lippert M. Treatment of painful prostatic bone metastases with oral etidronate disodium. Urology 1988; 32: 403–7PubMedCrossRef

143.

Schnur W. Etidronate for the relief of metastatic bone pain [abstract 424]. J Urol 1984; 131: 209 A

144.

Elomaa I, Blomqvist C, Grohn P, et al. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet 1983; I: 146–9CrossRef

145.

Paterson A, Powles T, Kanis J, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 59–65PubMed

146.

Elomaa I, Blomqvist C, Porkka L, et al. Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone 1987; 8 Suppl. 1:53–6

147.

Siris ES, Hyman GA, Canfield RE. Effects of dichloro-methylene diphosphonate in women with breast carcinoma metastatic to the skeleton. Am J Med 1983; 74: 401–6PubMedCrossRef

148.

Martoni A, Guaraldi M, Camera P, et al. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology 1991; 48: 97–101PubMedCrossRef

149.

Neri B, Gemelli MT, Sambataro S, et al. Subjective and metabolic effects of clodronate in patients with advanced breast cancer and symptomatic bone metastases. Anticancer Drugs 1992;3:87–90PubMedCrossRef

150.

Adami S, Salvagno G, Guarrera G, et al. Dichloromethylene diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol 1985; 134: 1152–4PubMed

151.

Adami S, Mian M. Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. Cancer Res 1989; 116: 67–72

152.

Elomaa I, Kylmälä T, Tammela T, et al. Effect of oral clodronate on bone pain. A controlled study in patients with metastatic prostatic cancer. Int Urol Nephrol 1992; 24: 159–66PubMedCrossRef

153.

Vorreuther R. Bisphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma. A pilot study on clodronate. Br J Urol 1993; 72: 792–5PubMedCrossRef

154.

Kylmälä T, Tammela T, Lindholm T, et al. The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer. Ann Chir Gynaecol 1994; 83:316–9PubMed

155.

Cresswell SM, English PJ, Hall RR, et al. Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer. Br J Urol 1995; 76: 360–5PubMedCrossRef

156.

Heidenreich A, Hofmann R, Engelmann UD. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to refractory prostate cancer. J Urol 2001; 165: 136–40PubMedCrossRef

157.

Lahtinen R, Laakso M, Palva I, et al. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet 1992; 340: 1049–52PubMedCrossRef

158.

McCloskey EV, MacLennan IC, Drayson M, et al. Effect of clodronate on skeletal morbidity in myelomatosis. Br J Haematol 1998; 100: 317–25PubMedCrossRef

159.

Delmas PD, Charhon S, Chapuy MC, et al. Long-term effects of dichloromethylene diphosphonate (C12MDP) on skeletal lesions in multiple myeloma. Metab Bone Dis Relat Res 1982; 4: 163–8PubMedCrossRef

160.

Siris ES, Sherman WH, Baquiran DC, et al. Effects of dichloromethylene diphosphonate on skeletal mobilisation of calcium in multiple myeloma. N Engl J Med 1980; 302: 310–5PubMedCrossRef

161.

Heim ME, Clemens MR, Queisser W, et al. Prospective randomized trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment-A multicenter study. Onkologie 1995; 18: 439–48CrossRef

162.

Merlini G, Attardo Parrinello G, Piccinini L, et al. Long term effects of parenteral dichloromethylene bisphosphonate on bone disease of myeloma patients treated with chemotherapy. Hematol Oncol 1990; 8: 23–30PubMedCrossRef

163.

O’Rourke N, McCloskey E, Houghton F, et al. Double-blind, placebo-controlled, dose response trial of oral clodronate in patients with bone metastases. J Clin Oncol 1995; 13: 929–34PubMed

164.

Robertson A, Reed N, Ralston S. Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol 1995; 13: 2427–30PubMed

165.

Francini G, Gonnelli S, Petrioli R, et al. Treatment of bone metastases with dichloromethylene bisphosphonate. J Clin Oncol 1992; 10: 591–8PubMed

166.

Jung A, Chantraine A, Donath A, et al. Use of dichloromethylene diphosphonate in metastatic bone disease. N Engl J Med 1983; 308: 1499–501PubMedCrossRef

167.

Delmas PD, Charhon SA, Chapuy MC, et al. Place des diphosphonates dans la thérapeutique de 1’Ostéolyse et des hypercalcémies malignes. Rev Rhum Mal Osteoartic 1984; 51: 663–6PubMed

168.

Van Holten-Verzantvoort AFM, Zwinderman AH, Aaronson NH, et al. The effect of supportive Pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. Eur J Cancer 1991; 27: 544–9PubMedCrossRef

169.

Purohit OP, Anthony C, Radstone CR, et al. High-dose intravenous Pamidronate for metastatic bone pain. Br J Cancer 1996; 70: 554–8CrossRef

170.

Glover D, Lipton A, Keller A, et al. Intravenous Pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. Cancer 1994; 74: 2949–55PubMedCrossRef

171.

Van Holten-Verzantvoort AT, Bijvoet OL, Cleton FJ, et al. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet 1987; II: 983–5CrossRef

172.

Tyrell CJ. On behalf of the Aredia Multinational Cooperative Group: role of Pamidronate in the management of bone metastases from breast cancer: Results of a non-comparative multicenter phase II trial. Ann Oncol 1994; 5 Suppl. 7: S37–40

173.

Thiéband D, Leyvraz S, von Fliedner V, et al. Treatment of bone metastases from breast cancer and myeloma with Pamidronate. Eur J Cancer 1991; 27: 37–41CrossRef

174.

Coleman RE, Woll PJ, Miles M, et al. Treatment of bone metastases from breast cancer with (3-amino-l-hydroxy-propylidene)-1,1-bisphosphonate (APD). Br J Cancer 1988; 58: 621–5PubMedCrossRef

175.

Coleman RE, Vinholes J, Abbey ME, et al. Double-blind randomized trial of Pamidronate (Aredia) for the palliative treatment of metastases in bone disease [abstract 1706]. Am Soc Clin Oncol Program/Proc 1996; 15: 528

176.

Hultborn R, Gundersen S, Ryden S, et al. Efficacy of Pamidronate in breast cancer with bone metastases: a randomized double-blind placebo-controlled multicenter study. Anticancer Res 1999; 19: 3383–92PubMed

177.

Hultborn R, Gundersen S, Ryden S, et al. Efficacy of Pamidronate in breast cancer with bone metastases: a randomized double-blind placebo-controlled multicenter study. Acta Oncol 1996; 35 Suppl. 5: 73–4PubMedCrossRef

178.

Millward MJ, Cantwell BMJ, Carmichael J, et al. Arandomised trial of the addition of disodium Pamidronate (APD) to endocrine therapy for advanced breast cancer with bone metastases [abstract 43]. Am Soc Clin Oncol Program/Proc 1991; 10: 42

179.

Radziwill AJ, Thürlimann B. Significant improvement of quality of life in patients with malignancy-related bone disease and bone pain after high dose Pamidronate: a randomised dose finding study. Ann Oncol 1992; 3 (Suppl. 5): A 725

180.

Panagos G, Boukis H, Papadakou M, et al. Treatment of extensive bone metastases due to refractory breast cancer with combination of disodium Pamidronate and epirubicin. Ann Oncol 1992; 3 (Suppl. 5): A352

181.

Thürlimann B, Morant R. Pamidronate for osteolytic bone metastases: is there a dose effect? Eur J Cancer 1991; 27 (Suppl. 2): S284

182.

Bachouchi M, Bruning PF, Soukop M, et al. Intravenous Pamidronate (APD) in the treatment of osteolytic metastases of breast cancer: preliminary results of a multicentre study. In: Bijvoet OLM, Lipton A, editors. Osteoclast inhibition in the management of malignancy-related bone disorders. Lewiston: Hogrefe and Huber, 1991: 38–44

183.

Hacking A, Gudgeon CA, McNaughton D, et al. Pamidronate (APD) as single-infusion monotherapy in the treatment of bone metastases from breast cancer. In: Bijvoet OLM, Lipton A, editors. Osteoclast inhibition in the management of malignancy-related bone disorders. Lewiston: Hogrefe and Huber, 1991:45–53

184.

Dodwell DJ, Howell A, Morton AR, et al. Pamidronate (APD) treatment of skeletal metastases from breast cancer. In Rubens ED, Editor. The management of bone metastases and hypercalcaemia by osteoclast inhibition. Toronto: Huber, 1990: 62–75

185.

Lipton A, Glover D, Harvey H, et al. Disodium Pamidronate (APD) — a dose seeking study in patients with breast and prostate cancer: a preliminary report. In: Bijvoet OLM, Lipton A, editors. Osteoclast inhibition in the management of malignancy-related bone disorders. Lewiston: Hogrefe and Huber, 1991: 33–37

186.

Pelger RCM, Lycklama à Nijeholt AAB, Papapoulos SE. Short-term metabolic effects of Pamidronate in patients with prostatic carcinoma and bone metastases. Lancet 1989; II: 865CrossRef

187.

Fleisch H. Bisphosphonates —preclinical. In: H. Fleish, editor. Bisphosphonates in bone disease. From laboratory to the patient. San Diego: Academic Press, 2000: 40–41

188.

Gonzalez DC, Mautalen CA. Short-term therapy with oral olpadronate in active paget’s disease of bone. J Bone Miner Res 1999; 14: 2042–7PubMedCrossRef

189.

Soerdjbalie-Maikoe V, Pelger RCM, Lycklama à Nijeholt AAB, et al. Palliation of bone pain by the bisphosphonate olpadronate in hormone-escaped prostate adenocarcinoma metastatic to the skeleton. J Urol 2000; 163: 261

190.

Coleman RE, Purohit OP, Black C, et al. Double-blind randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease. Ann Oncol 1999; 10: 311–6PubMedCrossRef

Titel: Strategies for Management of Prostate Cancer-Related Bone Pain
verfasst von: Rob C. M. Pelger
Vidija Soerdjbalie-Maikoe
Neveen A. T. Hamdy
Publikationsdatum: 01.12.2001
Verlag: Springer International Publishing
Erschienen in: Drugs & Aging / Ausgabe 12/2001
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI: https://doi.org/10.2165/00002512-200118120-00002

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2001

Tegafur/Uracil

Cytomegalovirus and the Aging Population

Selective Inhibitors of Butyrylcholinesterase